Drug intelligence / Profile preview

SHD003

Development stage: Preclinical
Lead developer: Shihuida Pharmaceutical Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

SHD003 is a recombinant humanized monoclonal antibody targeting programmed cell death 1 ligand 1 (PD-L1), currently under development by Shihuida Pharmaceutical Group (Shenyang Shihuida Pharmaceutical). The drug is designed to treat various solid tumors by inhibiting the interaction between PD-L1 on tumor cells and the PD-1 receptor on T cells, thereby restoring the immune system's ability to recognize and attack malignant cells. As of 2024, SHD003 is in the IND-enabling phase, representing a key component of Shihuida's expansion into the oncology immunotherapy market.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on SHD003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHD003.

Explore the full profile